Active substanceNicotinoyl gamma-aminobutyric acidNicotinoyl gamma-aminobutyric acid
Similar drugsTo uncover
  • Amilonosar®
    pills inwards 
    BIOCHEMIST, OJSC     Russia
  • Amilonosar®
    solution w / m in / in 
    BIOCHEMIST, OJSC     Russia
  • Pikamil®
    solution w / m in / in 
  • Picalon
    solution w / m in / in 
  • Picalon
    pills inwards 
    AKRIKHIN HFK, JSC     Russia
  • Pikamil®
    pills inwards 
  • Picanoloy®
    pills inwards 
    NPK ECHO, CJSC     Russia
  • Dosage form: & nbsppills
    Composition:

    Pikamilon or 20.00 mg or 50.00 mg

    N-nicotinoyl-gamma-aminobutyric acid sodium salt

    Excipients: potato starch - 18.70 mg or 46.78 mg, corn starch - 0.60 mg or 1.47 mg, magnesium hydroxycarbonate (magnesium carbonate basic) - 15.53 mg or 38.82 mg, sucrose - 42.55 mg or 106.38 mg, calcium stearate - 1.00 mg or 2.50 mg, talc 1.62 mg or 4.05 mg.

    Description:

    white planocylindrical tablets with a facet (20 mg dose) and facial and risky (50 mg dose).

    Pharmacotherapeutic group:nootropic agent.
    ATX: & nbsp

    N.06.B.X   Other psychostimulants and nootropic drugs

    Pharmacodynamics:

    Nootropic agent, dilates blood vessels brain. It alsoquilting, psycho-stimulating, antiplatelet and antioxidant actiontion.Improves the functional stateof the brain due to the normalization of metabolitesand the effect on the cerebral corteximagination (increases volumetric and linear speed of cerebral blood flow, reduces vascular resistance, inhibiting platelet aggregation, improves microcirculation). At the course reception increases physical and mental efficiency, reduces headache, improves memory, normalizes sleep; contributes to the reduction or disappearance of feelings of anxiety, tension, fear; improves the condition of patients with motor and speech disorders, reduces the inhibitory effect of ethanol on the central nervous system. Improves blood circulation in the vessels of the retina and optic nerve.

    Pharmacokinetics:

    Absorption is fast and complete. Penetrates through the blood-brain barrier, for a long time retaining in the tissues of the body. Bioavailability is 50-88%. It is excreted mainly by the kidneys in an unchanged form. The half-life is 0.51 hours.

    Indications:

    Complex therapy of ischemic cerebrovascular disorders of mild and moderate severity, chronic cerebrovascular insufficiency,state after craniocerebral trauma, treatment of chronic alcoholism (to reduce asthenic, asthenoneurotic, postpsychotic, pre-recurrent conditions, and alcoholic encephalopathy).

    As part of complex therapy for proMigraine headaches. As part of complex therapy of primary

    open-angle glaucoma with compensatorywith pressure, with diseases of thechutes and optic nerve of vascular gerne.

    In urological practice (in children older than 3 years and adults with disorders canto improve adaptationfunction of the bladder (decrease hypoxia detrusora).

    In complex therapy of dysto syndromeaccompanied by anxiety, fear, increased irritability, emotional lability.

    Contraindications:

    Hypersensitivity, chronic renal failure, pregnancy, lactation, children under 3 years.

    Dosing and Administration:

    Inside, regardless of food intake.

    In cerebrovascular diseases, a single dose of 20-50 mg 2-3 times a day, in a daily dose of 60-150 mg. The course of treatment is 1-2 months. The repeated course in 5-6 months.

    For the prevention of migraine attacks of 50 mg 3 times a day for stopping the attack - pyo mg once.

    Depressive states of late age - 40-200 mg per day for 2-3 doses, the optimal dosage is 60-120-mg per day, for 1.5-3 months.

    As an asthenic and anxiolytic agent, 40-80 mg per day, if necessary up to 200-300 mg per day, for 1-1.5 months.

    With alcoholism during the period of abstinence - 100-150 mg per day, short course 6-7 days; with more persistent violations outside of abstinence, a daily dose of 40-60 mg - for 4-5 weeks

    To restore working capacity and with increased loads of 60-80 mg per day for 1-1.5 months, for athletes in the same dose, for 2 weeks of training period.

    At a primary open-angle glaucoma - on 5fyr 3 times a day for 1 month.

    With diseases of the retina and optic nerve, the first 12 days are administered intramuscularly, then depending on the condition, they are administered orally 20-50 mg 3 times a day at a daily dose of 60-150 mg for 1 month.

    In disorders of urination 20 mg twice a day (for children from 3 to 10 years), 50 mg 2 times a day (for children from 11 to 15 years), 50 mg 3 times a day (for patients older than 15 years). Course of treatment 1 month.

    Side effects:

    Allergic reactions (skin rash, itching), dizziness, headache, mild nausea, irritability, anxiety, agitation.

    Overdose:Increased severity of symptoms of side effects.Treatment is symptomatic.
    Interaction:Shortens the action of barbiturates, enhances the action of opioid analgesics.
    Effect on the ability to drive transp. cf. and fur:
    Form release / dosage:

    Tablets of 20 or 50 mg. For 30 or 60 tablets in a polymer can. Each bank along with instructions for medical use - in a pack of cardboard.

    Packaging:(30) - polymer cans (1) - packs of cardboard
    (60) - polymer cans (1) - packs cardboard
    Storage conditions:

    At a temperature of no higher than 25 ° C. Keep out of the reach of children.

    Shelf life:3 years. Do not use after the expiration date printed on the package.
    Terms of leave from pharmacies:On prescription
    Registration number:P N000807 / 01
    Date of registration:18.07.2007
    The owner of the registration certificate:PHARMSTANDART-UFIM VITAMIN FACTORY, OJSC PHARMSTANDART-UFIM VITAMIN FACTORY, OJSC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp13.08.2015
    Illustrated instructions
      Instructions
      Up